Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGF-II CRISPR Activation Plasmid (m): sc-421058-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGF-II CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- IGF-II CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by IGF-II CRISPR Activation Plasmid (m) and IGF-II CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Igf2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGF-II Antibody (D-10): sc-518128
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF-II CRISPR Activation Plasmid (m) | sc-421058-ACT | 20 µg | $397.00 | |||
IGF-II CRISPR Activation Plasmid (m2) | sc-421058-ACT-2 | 20 µg | $397.00 |
Mouse Igf2 encodes insulin-like growth factor II (IGF-II), a secreted growth factor that signals primarily through IGF1R and insulin receptor isoform A to regulate embryonic and placental growth, cell proliferation, survival, and metabolic homeostasis. IGF-II activates downstream PI3K–AKT–mTOR and RAS–RAF–MEK–ERK pathways, influencing cell cycle progression, differentiation programs, and nutrient utilization. Igf2 is an imprinted locus with tightly controlled developmental expression, and dysregulation of IGF-II signaling has been linked to abnormal growth phenotypes, altered tissue regeneration, and oncogenic processes in multiple contexts. In mouse models, Igf2 perturbation is widely used to study growth control, epigenetic regulation of imprinting, and signaling cross-talk with insulin/IGF axes.
IGF-II CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Igf2 expression without altering the underlying DNA sequence.
IGF-II CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Igf2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Igf2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous IGF-II expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Igf2 locus and enabling the study of IGF-II-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of IGF-II pathway restoration in tumor cells with silenced or reduced Igf2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.